Charite Universitaetsmedizin Berlin KöR

26 trials 10 recruiting Academic / non-commercial

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

10 Recruiting

10 Completed trials

15 Countries active

71 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 5 Phase II: 9 Phase I/II: 7 Phase IV: 4 Phase I (Other): 1

Oversight events:

1 serious breach 2 temporary halts 1 corrective measure across 3 trials

View oversight register →

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rheumatoid arthritis 2 Acute respiratory distress syndrome 1 Microscopic polyangiitis 1 Head and neck cancer metastatic 1 Granulomatosis with polyangiitis 1 Axial spondyloarthritis 1 Psoriasis 1

Top IMPs

DEUCRAVACITINIB 3 KYV-101 2 METHOTREXATE 2 METHYLPREDNISOLONE 2 MITOXANTRONE 2 PARACETAMOL 2 PEGASPARGASE 2 TACROLIMUS 2 TREG02 2 VINCRISTINE SULFATE 2 ABATACEPT 1 AMPHOTERICIN B 1

All trials — page 2

26 total

Molecular effects of deucravacitinib on plaque psoriasis and hard-to-treat psoriasis sites. Ended

2023-508948-22-00 Phase IV 1 country DEUCRAVACITINIB
Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib. Ended

2024-510759-37-00 Phase IV 1 country DEUCRAVACITINIB

Showing 25–26 of 26 trials

← All sponsors A–Z